Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Abdel-Rahman, Omar M. [VerfasserIn]   i
 Mehrabi, Arianeb [VerfasserIn]   i
 Oweira, Hani [VerfasserIn]   i
Titel:Treatment-related death in cancer patients treated with immune checkpoint inhibitors
Titelzusatz:a systematic review and meta-analysis
Verf.angabe:O. Abdel-Rahman, D. Helbling, J. Schmidt, U. Petrausch, A. Giryes, A. Mehrabi, O. Schöb, M. Mannhart, H. Oweira
Jahr:2017
Jahr des Originals:2016
Umfang:13 S.
Fussnoten:Available online 25 November 2016 ; Gesehen am 24.09.2018
Titel Quelle:Enthalten in: Clinical oncology
Ort Quelle:[S.l.] : Saunders, 1989
Jahr Quelle:2017
Band/Heft Quelle:29(2017), 4, Seite 218-230
ISSN Quelle:1433-2981
Abstract:Aims We carried out a meta-analysis to determine the risk of treatment-related death associated with immune checkpoint inhibitor use in cancer patients. Materials and methods We examined data from the Medline and Google Scholar databases. We also examined original studies and review articles for cross-references. Eligible studies included randomised phase II and phase III trials of patients with cancer treated with ipilimumab, pembrolizumab; nivolumab; tremelimumab and atezolizumab. The authors extracted relevant information on participants, characteristics, treatment-related death and information on the methodology of the studies. Results After exclusion of ineligible records, 18 clinical trials were included in the analysis. The odds ratio for treatment-related death for CTLA-4 inhibitors (ipilimumab and tremelimumab) was 1.80 (95% confidence interval 1.25, 2.59; P=0.002) and for PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab and atezolizumab) was 0.63 (95% confidence interval 0.31, 1.30; P=0.22). Treated cancer seems to have no effect on the risk of treatment-related death. Conclusions Analysis of our data showed that CTLA-4 inhibitors (ipilimumab and tremelimumab) in a higher dose (10 mg/kg) seem to be associated with a higher risk of treatment-related death compared with control regimens, whereas PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab and atezolizumab) do not cause the same risk. Clinicians have to be fully aware of these differential risks and council their patients appropriately.
DOI:doi:10.1016/j.clon.2016.11.007
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: http://dx.doi.org/10.1016/j.clon.2016.11.007
 Volltext: http://www.sciencedirect.com/science/article/pii/S0936655516304071
 DOI: https://doi.org/10.1016/j.clon.2016.11.007
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Atezolizumab
 ipilimumab
 nivolumab
 pembrolizumab
 treatment-related death
 tremelimumab
K10plus-PPN:1581220928
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68308397   QR-Code
zum Seitenanfang